ReviewTranslational lung cancer research2013
Prognostic and predictive biomarkers in early stage NSCLC: CTCs and serum/plasma markers.
Review in Translational lung cancer research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 38 citations in OpenAlex.
- Prognostic factors for non-small cell lung cancer after neoadjuvant therapy and surgery: a retrospective observational study.Journal of thoracic disease · 2025Article
- Can blood-based markers predict RECIST progression in non-small cell lung cancer treated with immunotherapy?Journal of cancer research and clinical oncology · 2024Article
- Soluble galectin-3 as a microenvironment-relevant immunoregulator with prognostic and predictive value in lung adenocarcinoma.Molecular oncology · 2024Article
- Clinical and prognostic significance of detectingTranslational lung cancer research · 2023Article
- Importance of CT image normalization in radiomics analysis: prediction of 3-year recurrence-free survival in non-small cell lung cancer.European radiology · 2022Article
- Highly Sensitive Love Mode Acoustic Wave Platform with SiOBiosensors · 2022Article
- Relationship between survival and erythrocyte sedimentation rate in patients operated for lung cancer.Turk gogus kalp damar cerrahisi dergisi · 2022Article
- Wedge resection before lobectomy for patients with T1N0M0 non-small cell lung cancer: a propensity score matching analysis.Annals of translational medicine · 2022Article
- Matrix Metalloproteinases and Stress Hormones in Lung Cancer Progression.Journal of oncology · 2022Article
- Hsp70 in Liquid Biopsies-A Tumor-Specific Biomarker for Detection and Response Monitoring in Cancer.Cancers · 2021Article
- STK1p as a prognostic biomarker for overall survival in non-small-cell lung carcinoma, based on real-world data.Future science OA · 2020Article
- Proteomic and genomic biomarkers for Non-Small Cell Lung Cancer: Peroxiredoxin, Haptoglobin, and Alpha-1 antitrypsin.Cancer medicine · 2020Article
- A new BiRSC advances · 2020Article
- Novel Liquid Biomarker Panels for A Very Early Response Capturing of NSCLC Therapies in Advanced Stages.Cancers · 2020Article
- Selected Tumour Biomarker Levels in Sheep with Pulmonary Adenomatosis.Journal of veterinary research · 2020Article
- Preoperative Folate Receptor-Positive Circulating Tumor Cell Level Is a Prognostic Factor of Long Term Outcome in Non-Small Cell Lung Cancer Patients.Frontiers in oncology · 2020Article
- Circulating tumor cell levels and carcinoembryonic antigen: An improved diagnostic method for lung adenocarcinoma.Thoracic cancer · 2018Article
- [Progress of Liquid Biopsy in Early Diagnosis of Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2018Review
- Signaling protein signature predicts clinical outcome of non-small-cell lung cancer.BMC cancer · 2018Article
- Prognostic value of baseline carcinoembryonic antigen and cytokeratin 19 fragment levels in advanced non-small cell lung cancer.Cancer biomarkers : section A of Disease markers · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Resection of early stage non-small cell lung cancer (NSCLC) offers patients the best hope of cure, however recurrence rates post-resection remain high suggesting the presence of micro-metastatic disease at the time of surgery undetected by standard staging methods. A critical step in the metastatic cascade is the entry of tumor cells into the circulation enabling their distribution to and seeding of distant organs. This review explores the evidence for predictive and prognostic circulating biomarkers in the early stage NSCLC population. We summarize studies that have explored a variety of targets including circulating proteins, nucleic acids and more recently circulating tumor cells (CTCs) as potentially clinically relevant biomarkers in the early stage setting. Circulating biomarkers may add clinically relevant information about the biological behavior of tumors over and above that provided by pathological staging. Improvement in the stratification of patients according to the likelihood of metastatic relapse after radical treatments such as surgical resection could allow more effective targeting of systemic therapies such as adjuvant chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.